The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder

Does Methylphenidate, Prescribed for Attention Deficit Disorder, Influence Primary Enuresis in These Children?

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02699528

Enrollment

Registered

2016-03-04

Start date

2016-05-31

Completion date

2017-05-31

Last updated

2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder, Enuresis

Brief summary

To assess wether methylphenidate reduces the prevalence of primary nocturnal enuresis in children with attention deficit disorder

Detailed description

Children aged 5 - 10 years newly diagnosed with attention deficit hyperactivity disorder who report primary nocturnal enuresis, Investigators will obtain baseline data (from parents/caregivers) on their sleep habits and enuresis characteristics by questionnaire. After 6 weeks of methylphenidate therapy, prescribed for the attention deficit, a new questionnaire will be filled.

Interventions

DRUGmethylphenidate

The drug will be prescribed as indicated for attention deficit disorder

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to 10 Years

Healthy volunteers

Inclusion criteria

* New diagnosis of attention deficit hyperactivity disorder * History of primary nocturnal enuresis * Normal neurological examination

Exclusion criteria

* Anatomical abnormality of the genitourinary system * Concommitant treatment, pharmacological/behavioral for enuresis * Concommitant diurnal enuresis

Design outcomes

Primary

Measure	Time frame
A reduction in nocturnal enuresis frequency	6 weeks

Countries

Israel

Contacts

Primary ContactFlorence Katz, BA

florence.katz@clalit.org.il972-9-7471803

Backup ContactOmer Raviv, MD

omerol@walla.co.il972-52-8822052

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026